Skip to content

Robin Carhart-Harris

Imperial College London, Multidisciplinary Association for Psychedelic Studies

312 papers in the library · 30,055 citations · publishing 2007-2026

Papers

Sort Most recent Most cited

Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.

Psychological Medicine August 26, 2025 Michael Angyus, Sarah Osborn, Eline Haijen et al.

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

DOI: 10.1017/s0033291725101219 (opens in new tab) Full text (opens in new tab) Psychedelics Psychedelic substances Psychedelic experiences Psychedelic research +17

Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion

Research Square August 22, 2025 Richard J. Zeifman, George Danias, Gabrielle Agin-Liebes et al. 2 citations preprint

Abstract Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefits of psychedelic therapy. However, there remains limited understanding of the occurrence and importance of specific positive emotional experiences within psychedelic therapy. Therefore, we examined the effects of psychedelics on positive emotional...

DOI: 10.21203/rs.3.rs-7420529/v1 (opens in new tab) Full text (opens in new tab) Self-compassion Psychotherapist Compassion fatigue Clinical psychology

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat

Frontiers in Psychiatry August 6, 2025 Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell et al. 3 citations

Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological...

Perturbing whole‐brain models of brain hierarchy: An application for depression following pharmacological treatment

Annals of the New York Academy of Sciences July 21, 2025 Marcel Socoró-garrigosa, Yonatan Sanz Perl, Morten L. Kringelbach et al. 3 citations

Abstract Determining the scale of neural representations is a central challenge in neuroscience. While localized representations have traditionally dominated, evidence suggests information is also encoded in distributed, hierarchical networks. Recent research indicates that the hierarchy of causal influences shaping functional patterns serves as a signature of distinct brain states, with...

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Comprehensive Psychiatry July 1, 2025 Luca Pellegrini, Naomi A Fineberg, Sorcha O'Connor et al. 17 citations

Obsessive-compulsive disorder (OCD) is a common and disabling condition. A large proportion of patients fail to respond to first-line treatment with serotonin reuptake inhibitors either selective serotonin reuptake inhibitors (SSRIs) or clomipramine. Preliminary evidence suggests psilocybin, a serotonin receptor agonist, might be efficacious. We conducted a pharmacological challenge study to...

DOI: 10.1016/j.comppsych.2025.152619 (opens in new tab) Full text (opens in new tab) Compulsions Ossessive-compulsive disorder Psychedelics OCD Treatment +2

Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings

Brain and Behavior July 1, 2025 Megan Calnan, Grace Blest‐hopley, Chris Busch et al. 4 citations

Abstract Background : Military veterans are at risk of various mental health conditions, with profound implications for post‐deployment quality of life. Current treatment options encounter high dropout rates and non‐responsiveness, and overlook the importance of community building in veterans’ holistic recovery. Preliminary research suggests psychedelics offer therapeutic benefits for...

Exploring serotonergic psychedelics as a treatment for personality disorders.

Neuropharmacology July 1, 2025 Brennan M. Carrithers, Daniel E. Roberts, Brandon M Weiss et al. 4 citations

Both psychotherapeutic interventions and pharmacological agents have demonstrated limited efficacy in the treatment of personality disorders (PDs). Emerging evidence suggests that psychedelic therapy, already showing promise in treating various psychiatric conditions commonly comorbid with PDs, may exert therapeutic effects by promoting adaptive changes in personality. Thus, psychedelic therapy...

DOI: 10.1016/j.neuropharm.2025.110413 (opens in new tab) Full text (opens in new tab) Psychedelic drugs Character disorders Magic mushroom therapy Personality disorders +6

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Molecular Psychiatry July 1, 2025 Rebecca Harding, Neomi Singer, Matthew B. Wall et al. correction

The following part of the abstract had a minor error: ‘Following PT, there was greater activation in the ventromedial prefrontal cortex and sensory regions, and reduced activation in the angular gyrus.’ This is now corrected to ‘Following PT, there was decreased activation in the ventromedial prefrontal cortex and angular gyrus, and greater activation in sensory regions.’ The original article...

DOI: 10.1038/s41380-025-03066-1 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Depression treatment Mood improvement Mental health therapy +22

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial.

European Neuropsychopharmacology June 23, 2025 Jessica S. Henry, Bruna Giribaldi, David Nutt et al. 2 citations

Patients with Major Depressive Disorder (MDD) have more dysfunctional attitudes than healthy individuals and these pessimistic biases are correlated with depression severity. Psilocybin has demonstrated sustained remission in depression. Secondary analysis of a two-arm randomized controlled trial assessing the effect of psilocybin therapy versus escitalopram on 'maladaptive' cognitive biases...

DOI: 10.1016/j.euroneuro.2025.06.003 (opens in new tab) Full text (opens in new tab) Escitalopram Depression treatment Medication Condition +13

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

Frontiers in Psychology June 6, 2025 William Roseby, Hannes Kettner, Leor Roseman et al. 6 citations

Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carry personal meaning. While research has demonstrated the capacity for these compounds to promote psychological wellbeing, it has yet to be shown to what extent they modulate "meaning in life", a specific contributor to mental and physical health....

DOI: 10.3389/fpsyg.2025.1580663 (opens in new tab) Naturalism Meaning existential Cognitive psychology Psychotherapist +3

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

American Journal of Psychiatry May 7, 2025 Matthew B. Wall, Lysia Demetriou, Bruna Giribaldi et al. 16 citations

Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.

DOI: 10.1176/appi.ajp.20230751 (opens in new tab) Full text (opens in new tab) Psilocybin Cognitive neuroscience Depressive disorders Psychopharmacology +7

Psilocybin for disorders of consciousness: A case-report study.

Clinical Neurophysiology May 1, 2025 Paolo Cardone, Pablo Núñez, Naji Alnagger et al. 7 citations

With very few treatments available, post-comatose disorders of consciousness (DoC) pose one of the hardest challenges in modern neurology. Following promising clinical trial results in psychiatry, and a deepening understanding of their brain mechanisms, psychedelics have been suggested as a novel therapeutic drug for DoC patients, given that they increase the entropy or complexity of...

DOI: 10.1016/j.clinph.2025.02.264 (opens in new tab) Full text (opens in new tab) Brain complexity Disorders of consciousness Psychedelics Severe brain injury +7

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises

Molecular Psychiatry April 26, 2025 Rebecca Harding, Neomi Singer, Talma Hendler et al. 4 citations

Abstract Psilocybin therapy (PT) is emerging as an effective intervention for Major Depressive Disorder (MDD), offering comparable efficacy to conventional treatments like selective serotonin reuptake inhibitors (SSRIs). Music, an emotionally evocative stimulus, provides a valuable tool to explore changes in hedonic and predictive processing mechanisms via expectancy violations, or ‘surprises’....

Network control energy reductions under DMT relate to serotonin receptors, signal diversity, and subjective experience.

Communications Biology April 18, 2025 S Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al. 17 citations

Psychedelics offer a profound window into the human brain through their robust effects on perception, subjective experience, and brain activity patterns. The serotonergic psychedelic N,N-dimethyltryptamine (DMT) induces a profoundly immersive altered state of consciousness lasting under 20 min, allowing the entire experience to be captured during a single functional magnetic resonance imaging...

Dynamic medial parietal and hippocampal deactivations under DMT relate to sympathetic output and altered sense of time, space, and the self

Imaging Neuroscience April 16, 2025 Lorenzo Pasquini, Alexander J. Simon, Courtney L. Gallen et al. 4 citations

Abstract N,N-Dimethyltryptamine (DMT) is a serotonergic psychedelic, known to rapidly induce short-lasting alterations in conscious experience, characterized by a profound and immersive sense of physical transcendence alongside rich and vivid auditory distortions and visual imagery. Multimodal neuroimaging data paired with dynamic analysis techniques offer a valuable approach for identifying...

Decreased CO2 saturation during circular breathwork supports emergence of altered states of consciousness.

Communications Psychology April 13, 2025 Martha N. Havenith, Max Leidenberger, Jelena Brasanac et al. 14 citations

Abstract Altered states of consciousness (ASCs), induced e.g. during psychedelic-assisted therapy, show potential to treat prevalent mental health disorders like depression and posttraumatic stress disorder. However, access to such treatments is restricted by legal, medical, and financial barriers. Circular breathwork may present a non-pharmacological and hence more accessible alternative to...

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use.

PNAS Nexus April 1, 2025 Katie Zhou, David de Wied, Robin Carhart-Harris et al. 9 citations

Interest in using psychedelic drugs to treat psychiatric disorders is growing rapidly. While modern controlled clinical trials show a favorable safety and efficacy profile, it remains unclear if the risk of side effects would increase with broader use in more heterogeneous populations. To address this, we investigated the frequency and baseline predictors of delusional ideation, magical...

DOI: 10.1093/pnasnexus/pgae560 (opens in new tab) Full text (opens in new tab) Hppd Adverse effects Delusional ideation Magical thinking +3

The Role of the Dorsolateral Prefrontal Cortex in Ego Dissolution and Emotional Arousal During the Psychedelic State.

Human Brain Mapping April 1, 2025 Clayton R. Coleman, Kenneth Shinozuka, Robert Tromm et al. 4 citations

Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic that induces a profoundly altered conscious state. In conjunction with psychological support, it is currently being explored as a treatment for generalized anxiety disorder and depression. The dorsolateral prefrontal cortex (DLPFC) is a brain region that is known to be involved in mood regulation and disorders; hypofunction...

DOI: 10.1002/hbm.70209 (opens in new tab) Full text (opens in new tab) Psychedelics Consciousness Brain-imaging Altered-states

LSD reconfigures the frequency-specific network landscape of the human brain

bioRxiv March 24, 2025 Kenneth Shinozuka, Mattia Rosso, Clayton R. Coleman et al. 3 citations preprint

Abstract Lysergic acid diethylamide (LSD) and other psychedelic substances profoundly alter human consciousness. While several studies have demonstrated changes in brain function and connectivity associated with psychedelics, we still have a limited understanding of how LSD reshapes brain networks operating across different frequency bands. In this study, we applied the recently developed...

Psychedelics Align Brain Activity with Context

bioRxiv (Cold Spring Harbor Laboratory) March 11, 2025 Devon Stoliker, Leonardo Novelli, Moein Khajehnejad et al. 8 citations preprint

Abstract Psychedelics can profoundly alter consciousness by reorganising brain connectivity; however, their effects are contextsensitive. To understand how this reorganisation depends on the context, we collected and comprehensively analysed the largest psychedelic neuroimaging dataset to date. Sixty-two adults were scanned with functional MRI and EEG during rest and naturalistic stimuli...

DOI: 10.1101/2025.03.09.642197 (opens in new tab) Full text (opens in new tab) Psilocybin Consciousness Context archaeology Cognitive psychology +6

Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT).

Communications Biology March 11, 2025 Juan Ignacio Piccinini, Yonatan Sanz Perl, Carla Pallavicini et al. 6 citations

The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects. We use a time-dependent whole-brain model to reproduce large-scale brain dynamics measured with fMRI from 15 volunteers under 20 mg intravenous N,N-Dimethyltryptamine (DMT), a short-acting psychedelic. To capture its transient effects, we...

DOI: 10.1038/s42003-025-07576-0 (opens in new tab) Full text (opens in new tab) DMT Brain chemistry Consciousness research Psychedelics

Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression

bioRxiv (Cold Spring Harbor Laboratory) March 10, 2025 Shaun K.l. Quah, Cameron C. Glick, Leor Roseman et al. preprint

Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain networks. Yet, it is unclear whether similar alterations are observed when nonlinear FC is examined. This study investigated how antidepressant treatment (i.e., psilocybin and escitalopram) modulates both linear FC and nonlinear FC in individuals with MDD....

DOI: 10.1101/2025.03.05.641592 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Functional connectivity Depression economics +4

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations

To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...

Can psychedelic use benefit meditation practice? Examining individual, psychedelic, and meditation-related factors.

PLoS One February 12, 2025 Zishan Jiwani, Simon B. Goldberg, Jack Stroud et al. 3 citations

INTRODUCTION: Meditation practice and psychedelic use have attracted increasing attention in the public sphere and scientific research. Both methods induce non-ordinary states of consciousness that may have significant therapeutic benefits. Thus, there is growing scientific interest in potential synergies between psychedelic use and meditation practice with some research suggesting that...

On Minimizing Risk and Harm in the Use of Psychedelics.

Psychiatric Research and Clinical Practice February 11, 2025 Jules Evans, Marc Aixalà, Brian T Anderson et al. 18 citations

Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net. Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety. Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors...

DOI: 10.1176/appi.prcp.20240128 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health safety Therapeutic protocols Harm reduction +1